<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1148">
  <stage>Registered</stage>
  <submitdate>2/05/2006</submitdate>
  <approvaldate>2/05/2006</approvaldate>
  <nctid>NCT00321191</nctid>
  <trial_identification>
    <studytitle>Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients</studytitle>
    <scientifictitle>Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>02531</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anesthesia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - No nitrous oxide
Treatment: drugs - Administration of N2O

Experimental: N2O - 

Placebo Comparator: No N2O - 


Treatment: drugs: No nitrous oxide


Treatment: drugs: Administration of N2O


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fa/FI sevoflurane in 100% O2 vs in 70% N2O and 30% O2 during 1st 60 min anaesthesia</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Fa/FI sevoflurane in 100% O2 vs in 70% N2O and 30% O2 after 60 minutes anaesthesia</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fa/FI and FA/FI for N2O will also be recorded.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients scheduled for elective surgery requiring relaxant general anaesthesia with
             arterial blood pressure monitoring via an arterial line.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Patients with moderately or severely impaired respiratory disease (FEV1 &lt; 1.5L, or FVC
             &lt; 2.0L).

          -  Patients under 18 years of age.

          -  Morbidly obese patients: BMI &gt; 30

          -  Patients unable to give informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>14</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Austin Hospital - Melbourne</hospital>
    <postcode>3084 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is investigating the "second gas effect", a phenomenon produced by the uptake of
      nitrous oxide (N2O) by the lungs, during the course of a typical anaesthetic. The effect is
      to increase the concentration of other breathed gases in the lung. These include oxygen and
      volatile anaesthetic agents such as sevoflurane, which are also normally administered along
      with N2O. We wish to i) measure the magnitude of the second gas effects on both blood and
      expired concentrations of sevoflurane (Part 1), and ii) see if a demonstrable difference
      exists between the effects on blood and expired concentrations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00321191</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Philip J Peyton, MD FANZCA</name>
      <address>Austin Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>